Laser Interstitial Thermal Therapy for Ultra-Early, Pre-Radiotherapy Glioblastoma Recurrence
Glioblastoma (GBM) remains aggressive despite standard therapy (surgery (CRET) + RT/CT). Over 40% of patients develop recurrence between surgery and pre-RT MRI, with median overall survival (OS) of 13.3m and 24.4m for patients with and without recurrence in pre-RT MRI, respectively. Reoperation is avoided as it delays adjuvant therapy. LITT offers a minimally invasive alternative that may: * Treat recurrence without delaying RT/CT * Potentially sensitize tumors to subsequent therapy This study tests if LITT can be practically integrated within the critical 1-week window between pre-RT MRI and radiotherapy initiation, maintaining the adjuvant schedule.
• Histologically confirmed glioblastoma, IDH-wildtype, regardless of MGMT status
• ≥18 years of age
• CRET
• Karnofsky Performance Status (KPS) ≥70
• No contra-indication for radio-chemotherapy
• Scheduled for adjuvant radio-chemotherapy at University Hospital of Bern
• Able to provide informed consent
• No contra-indication for LITT
• No pregnancy or active breast-feeding
• No known coagulopathy independent of medication
• No dissemination or multifocal disease
• Patients lacking capacity to consent or considered vulnerable (e.g., minors, those under legal protection) are not included.